ClinicalTrials.gg
RecruitingNCT07615985Updated Sep 23, 2026

Phase 1a Study Assessing Safety, Tolerability, Pharmacokinetics, and Immunogenicity of PMG1016

A Phase 1 interventional study of PMG1016 Dose 1 and PMG1016 Dose 2 in Chronic Kidney Disease, sponsored by Pulmongene Ltd.. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Pulmongene Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 102 studies in Renal Insufficiency, Chronic with a site in Australia — 19 open to participants now, 29 under way, 16 of them phase 3. Renal Insufficiency, Chronic · Australia.

Planned enrollment
86th of 92
30 · median 347
Started
2026
with 4 others
Phase 1
5 of 102
4 open now
Primary completion
2026-11
later than 7 of 28 live
Registered
100th of 102
by date

Among the 102 studies in Renal Insufficiency, Chronic with a site in Australia, this one is the 86th largest by planned enrollment of the 92 interventional ones that give a count, is one of 5 that started in 2026, is one of 5 in phase 1, reaches primary completion later than 7 of the 28 other live ones, and was the 100th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

19 of the 102 studies in Renal Insufficiency, Chronic with a site in Australia are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Renal Insufficiency, Chronic with a site in Australia, or all of them as a file.
02

Study summary

This study is a first-in-human (FIH), randomized, double-blind, placebo-controlled study of PMG1016 in healthy adult participants. It aims to investigate the safety, tolerability, PK, and immunogenicity of PMG1016 administered via IV infusion.

Cohort 1: Healthy participants receiving single doses of PMG1016 Dose 1 or placebo.

Cohort 2: Healthy participants receiving single doses of PMG1016 Dose 2 or placebo.

Cohort 3: Healthy participants receiving single doses of PMG1016 Dose 3 or placebo.

Cohort 4: Healthy participants receiving single doses of PMG1016 Dose 4 or placebo.

Read the detailed description

Participants will be enrolled and randomized into 1 of 4 cohorts in a double-blind manner

03

Conditions studied

  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be in good health based on medical history, physical exam, vital signs, , and lab results at screening, as judged by the PI.
  • 17.5-32.0 kg/m² and body weight 50-100 kg for males or 45-100 kg for females
  • No lab abnormalities (hematology, coagulation, biochemistry, urinalysis) per PI discretion
  • Females: Must be non-pregnant, non-lactating, and use double (condom + hormonal method/vaginal ring/IUD) through study completion, unless surgically sterile, , or in same-sex relationships. Negative pregnancy tests required. No oocyte donation for 90 days post dose.
  • Males: Must be surgically sterile, abstinent, or use condoms plus a highly effective method for female partners. Vasectomized males without proof of azoospermia must use condoms with partners. No sperm donation for 90 days post dose.

Exclusion criteria

Exclusion Criteria:

  • History or evidence of any medical condition (e.g., cardiovascular, gastrointestinal, endocrine, hematologic, psychiatric, renal, musculoskeletal, infectious, neurological, or other major disease) as determined by the PI.
  • A PR \<40 or >100 bpm or mean SBP >140 mmHg or DBP >95 mmHg (based on triplicate supine measurements after 5 minutes' rest).
  • Mean >450 ms (males) or >470 ms (females) at Screening; one repeat triplicate allowed at PI discretion
  • Any clinically significant ECG abnormalities (rhythm, conduction, morphology) that may affect QTc interpretation, per PI judgment
  • , AST, or creatinine >1.5 × , or total or lymphocytes > ULN.
  • (HGB) below the lower limit of the normal range (ULN) prior to enrollment.
  • Participants with a positive toxicology screening panel or positive alcohol breath test at Screening and on Day -1.
  • Regular alcohol consumption defined as > 21 alcohol units per week. Participant is unwilling to abstain from alcohol beginning 48 hours prior to admission to the CRU and while residing at the CRU.
  • Blood donation or significant blood loss (≥500 mL) within 60 days prior to the first IP administration.
  • Plasma donation within 7 days prior to the first IP administration.
  • Use of any product/device within 30 days or 5 half-lives (whichever is longer), or participation in >4 investigational drug studies in the past year.
  • Pregnant or lactating at Screening or planning pregnancy (self or partner) during the study or follow-up.
  • Fever >37.5°C or symptomatic infection within 2 weeks before Screening; any infection requiring systemic antibiotics within 3 months; history of recurrent infections; or a positive SARS-CoV-2 PCR before CRU admission.
  • Active , history of malignancy, or untreated precancerous lesions. Adequately treated or fully excised precancerous lesions are allowed.
  • Participants with a known history of retinal diseases, including conditions such as prior retinal detachment.
  • Participants with a history of recurrent epistaxis or gingival bleeding.
  • Use of prescription medications (except hormonal ) within 2 weeks before dosing; mAb products within 5 half-lives; or OTC drugs, supplements, or herbal products within 7 days before dosing.
  • History of anaphylaxis or severe allergy per PI judgment; mild untreated hay fever may be allowed.
  • History of allergic reaction or to any of the in the IP.
  • Positive screening test for -1/2, , antibody, or syphilis.
  • Any condition that, in the PI's judgment, may pose a risk to the participant or the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Drug: PMG1016 Dose 1

  • Experimental
    Cohort 2

    Drug: PMG1016 Dose 2

  • Experimental
    Cohort 3

    Drug: PMG1016 Dose 3

  • Experimental
    Cohort 4

    Drug: PMG1016 Dose 4

Interventions

  • DrugPMG1016 Dose 1

    Participants will be administered PMG1016 Dose 1 or Placebo in a 100mL IV infusion Volume

    Also known as: PMG1016

  • DrugPMG1016 Dose 2

    Participants will be administered PMG1016 Dose 2 or Placebo in a 100mL IV infusion Volume

    Also known as: PMG1016

  • DrugPMG1016 Dose 3

    Participants will be administered PMG1016 Dose 3 or Placebo in a 100mL IV infusion Volume

    Also known as: PMG1016

  • DrugPMG1016 Dose 4

    Participants will be administered PMG1016 Dose 4 or Placebo in a 100mL IV infusion Volume

    Also known as: PMG1016

06

What researchers measure

Primary outcomes

  1. Treatment-emergent adverse events (TEAEs)

    The incidence and severity occurred

    Time frame: Day 1 to Day 57

  2. Serious adverse events (SAEs)

    The incidence and severity occurred

    Time frame: From Day 1 to Day 57

  3. Number of participants with abnormal pulse rate

    Time frame: From Day 1 to Day 57

  4. Number of participants with abnormal blood pressure

    Time frame: From Day 1 to Day 57

  5. Number of participants with abnormal respiratory rate

    Time frame: From Day 1 to Day 57

  6. Number of participants with abnormal tympanic temperature

    Time frame: From Day 1 to Day 57

  7. Number of Participants with Clinically Significant Abnormal PR Interval

    Time frame: From Day 1 to Day 57

  8. Number of Participants with Clinically Significant Abnormal QRS Duration

    Time frame: From Day 1 to Day 57

  9. Number of Participants with Clinically Significant Abnormal QT interval

    Time frame: From Day 1 to Day 57

  10. Number of Participants with Clinically Significant Abnormal RR interval

    Time frame: From Day 1 to Day 57

  11. Number of Participants with Clinically Significant Valvular Abnormalities

    The number of participants with clinically significant valvular abnormalities identified by transthoracic echocardiography (TTE)

    Time frame: Day 1 to Day 29

  12. Number of Participants with Clinically Significant Abnormal Left Ventricular Ejection Fraction

    The number of participants with clinically significant abnormalities in left ventricular ejection fraction (LVEF) assessed by transthoracic echocardiography (TTE)

    Time frame: Day 1 to Day 29

  13. Number of Participants with Clinically Significant Abnormal Hematology Results

    Time frame: Day 1 to Day 57

  14. Number of Participants with Clinically Significant Abnormal Clinical Chemistry Results

    Time frame: Day 1 to Day 57

  15. Number of Participants with Clinically Significant Abnormal Urinalysis Results

    Time frame: Day 1 to Day 57

  16. Number of Participants with Clinically Significant Abnormal Physical Examination Findings

    assessment of general appearance; head; ears; eyes; nose; throat; dentition; thyroid; chest (heart and lungs); abdomen; skin; neurological system; extremities; back; neck; musculoskeletal system; and lymph nodes

    Time frame: Day 1 to Day 57

Secondary outcomes

  1. Incidence of anti-drug antibodies (ADA)

    Percentage of PMG1016-induced ADA positive participants and percentage of PMG1016-boosted ADA positive participants

    Time frame: From Day 1 to Day 57

  2. Maximum serum PMG1016 concentration (Cmax)

    Determine PMG1016 Cmax in Serum

    Time frame: Varying timepoints through end of treatment, up to Day 57

  3. Time to maximum concentration (Tmax)

    Determine PMG1016 Tmax in Serum.

    Time frame: Varying timepoints through end of treatment, up to Day 57

  4. Area under the serum drug concentration-time curve (AUC) from time zero to the last time point with measurable concentration (AUC0-t)

    Determine PMG1016 AUC and AUC0-t in Serum.

    Time frame: Varying timepoints through end of treatment, up to Day 57

  5. AUC from time zero to infinity (AUC0-∞)

    Determine PMG1016 AUC0-∞ in Serum.

    Time frame: Varying timepoints through end of treatment, up to Day 57

  6. The extrapolated portion of AUC0-∞ from Tlast to infinity (%AUCextrap)

    Determine PMG1016 %AUCextrap in Serum.

    Time frame: Varying timepoints through end of treatment, up to Day 57

  7. Terminal elimination half-life (t1/2)

    Determine PMG1016 t1/2 in Serum.

    Time frame: Varying timepoints through end of treatment, up to Day 57

  8. Apparent total body clearance (CL)

    Determine PMG1016 CL in Serum.

    Time frame: Varying timepoints through end of treatment, up to Day 57

  9. Apparent volume of distribution during the terminal phase (Vz)

    Determine PMG1016 Vz in Serum.

    Time frame: Varying timepoints through end of treatment, up to Day 57

  10. Apparent terminal elimination rate constant (λz)

    Determine PMG1016 λz in Serum.

    Time frame: Varying timepoints through end of treatment, up to Day 57

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.

Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 6 months is below that.

Counting every sponsor, half of 109 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2026
First posted
May 29, 2026
StartActual
May 29, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07615985
Lead sponsor
Pulmongene Ltd.
Responsible party
Sponsor
First posted
May 29, 2026
Start date
May 29, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Sep 23, 2026

Study contacts

Yaohui Wang
Contact
yaohui_wang@pulmongene.com
+86 13810669548

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion